Cochrane corner: Phototherapy for atopic eczema

Gregory, Ian; Marshall, Hannah

doi:10.1111/cea.14230

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This month's Cochrane Corner summarizes evidence for phototherapy to treat atopic eczema 8 . It is disappointing to see how weak the clinical trial evidence is for phototherapy, given that this treatment has been part of the eczema armamentarium for over 50 years.…”

Section: Reproducibility Problem Examples Solutionsmentioning

confidence: 99%

“…This month's Cochrane Corner summarizes evidence for phototherapy to treat atopic eczema. 8 It is disappointing to see how weak the clinical trial evidence is for phototherapy, given that this | 5 EDITO RIA L treatment has been part of the eczema armamentarium for over 50 years. Figure 1 shows the key patient-centred outcome of interest, with increased probability of a self-reported reduction in itch with narrow-band ultraviolet B treatment compared with no phototherapy.…”

Section: What Does Clinical and Experimental Allergy Mean By 'Trusted...mentioning

confidence: 99%

See 1 more Smart Citation

What does Clinical and Experimental Allergy mean by ‘Trusted Evidence in Allergy’?

Boyle

Shamji

2023

Clin Experimental Allergy

View full text Add to dashboard Cite

Section: Reproducibility Problem Examples Solutionsmentioning

confidence: 99%

Section: What Does Clinical and Experimental Allergy Mean By 'Trusted...mentioning

confidence: 99%

What does Clinical and Experimental Allergy mean by ‘Trusted Evidence in Allergy’?

Boyle

Shamji

2023

Clin Experimental Allergy

View full text Add to dashboard Cite

“…Eczema is a common chronic cutaneous inflammatory disease affecting 10-30% of children and 2-10% of adults worldwide [7]. Some reports indicate that eczema affects the cancer risk, but the results are controversial [8,9].…”

Section: Introductionmentioning

confidence: 99%

Eczema as a protective factor for brain cancer: a meta-analysis

Zhu

Teng

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background Brain cancer is one of the most aggressive cancer types owing to poor treatment effects. Epidemiological studies have demonstrated that allergies may increase the disease risk. Therefore, this study evaluated the association between eczema and the risk of various brain cancers. Methods We systematically searched the PubMed and Embase databases from their inception until June 23, 2022. Two reviewers independently reviewed and screened the articles, extracted data, assessed the study quality, and pooled the results. Stata software was used to generate pooled odds ratios and 95% confidence intervals (CIs). Results We included 20 studies comprising 5,117,222 patients that investigated the relationship between eczema and brain cancer. Eczema was significantly inversely associated with the risk of brain cancer (odds ratio [OR], 0.82; 95% CI, 0.77–0.87), glioma (OR, 0.53; 95% CI, 0.14–2.02), meningioma (OR, 0.74; 95% CI, 0.66–0.84), and acoustic neuroma (OR, 0.60; 95% CI, 0.41–0.88). Interesting, The strong correlation between eczema and the reduced risk of brain cancer was observed in people over 16 years old (OR, 0.79; 95% CI, 0.71–0.88), but not in those under 16 years old (OR, 0.94; 95% CI, 0.79–1.11). In addition, subgroup analyses found that eczema significantly decreased the glioma risk in Europeans (OR, 0.73; 95% CI, 0.65–0.82) but not Australians (OR, 0.53; 95% CI, 0.14–2.02) or Americans (OR, 1.01; 95% CI, 0.69–1.46). Conclusion Eczema may be considered as a potential protective factor of brain cancer in population aged over 16 years. However, this relationship requires verification using large-scale clinical data.

show abstract

Retrospective evaluation of the effectiveness and safety of UVB-311 in atopic dermatitis

Kochergin,

Abdulridha

2024

Russian Journal of Skin and Venereal Diseases

View full text Add to dashboard Cite

BACKGROUND: Atopic dermatitis is a widespread skin disease based on immune and genetic mechanisms of chronic inflammation formation. The disease most often develops in early childhood, has a frequent recurrent course, age-related clinical features. In this regard, the disease is characterized by a wide variety of treatment methods, the effectiveness of which varies and is a highly debated topic at the present time. AIM: to retrospectively evaluate the efficacy and safety of standard local and systemic therapy of atopic dermatitis in combination with UVB 311 nm. MATERIALS AND METHODS: 100 case histories of patients with atopic dermatitis of varying severity who were in the clinic of skin and venereal diseases in the period from 2022 to 2023 were analyzed. Of these, 50 patients received combined systemic and topical therapy with UVB 311 nm (the first group), and 50 patients received only standard topical and systemic therapy (the second group). Systemic and topical therapy of atopic dermatitis included, according to clinical recommendations, corticosteroids, calcineurin inhibitors, antihistamines. RESULTS: As a result of combined therapy with UVB 311 nm, patients showed a decrease in the SCORAD index by 1.7 times after 1 month of therapy, by 8 times after 2 months, and by 30 times after 6 months. In the second group, the SCORAD index decreased 1.2 times after 1 month from the start of therapy (p=0.0004), 3 times after 2 months (p=0.0001), 20 times after 6 months (p=0.003). Side effects in the first group were detected only in 5 (10%) patients: 2 (4%) patients had skin burning, 2 (4%) had skin itching, 1 (2%) patient had photodermatitis in the form of erythema of the skin. These adverse reactions were of a short-term nature and quickly passed if the recommendations were followed without canceling the procedures. CONCLUSION: UVB 311 nm therapy for atopic dermatitis has a higher therapeutic effect, is well tolerated, has minimal early side effects, and leads to clinical remission faster than standard systemic and local therapy.

show abstract

Cochrane corner: Phototherapy for atopic eczema

Cited by 3 publications

References 7 publications

What does Clinical and Experimental Allergy mean by ‘Trusted Evidence in Allergy’?

What does Clinical and Experimental Allergy mean by ‘Trusted Evidence in Allergy’?

Eczema as a protective factor for brain cancer: a meta-analysis

Retrospective evaluation of the effectiveness and safety of UVB-311 in atopic dermatitis

Contact Info

Product

Resources

About